Cargando…
Valuation of scleroderma and psoriatic arthritis health states by the general public
OBJECTIVE: Psoriatic arthritis (PsA) and scleroderma (SSc) are chronic rheumatic disorders with detrimental effects on health-related quality of life. Our objective was to assess health values (utilities) from the general public for health states common to people with PsA and SSc for economic evalua...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959096/ https://www.ncbi.nlm.nih.gov/pubmed/20920309 http://dx.doi.org/10.1186/1477-7525-8-112 |
_version_ | 1782188439403233280 |
---|---|
author | Khanna, Dinesh Frech, Tracy Khanna, Puja P Kaplan, Robert M Eckman, Mark H Hays, Ron D Ginsburg, Shaari S Leonard, Anthony C Tsevat, Joel |
author_facet | Khanna, Dinesh Frech, Tracy Khanna, Puja P Kaplan, Robert M Eckman, Mark H Hays, Ron D Ginsburg, Shaari S Leonard, Anthony C Tsevat, Joel |
author_sort | Khanna, Dinesh |
collection | PubMed |
description | OBJECTIVE: Psoriatic arthritis (PsA) and scleroderma (SSc) are chronic rheumatic disorders with detrimental effects on health-related quality of life. Our objective was to assess health values (utilities) from the general public for health states common to people with PsA and SSc for economic evaluations. METHODS: Adult subjects from the general population in a Midwestern city (N = 218) completed the SF-12 Health Survey and computer-assisted 0-100 rating scale (RS), time trade-off (TTO, range: 0.0-1.0) and standard gamble (SG, range: 0.0-1.0) utility assessments for several hypothetical PsA and SSc health states. RESULTS: Subjects included 135 (62%) females, 143 (66%) Caucasians, and 62 (28%) African-Americans. The mean (SD) scores for the SF-12 Physical Component Summary scale were 52.9 (8.3) and for the SF-12 Mental Component Summary scale were 49.0 (9.1), close to population norms. The mean RS, TTO, and SG scores for PsA health states varied with severity, ranging from 20.2 to 63.7 (14.4-20.3) for the RS 0.29 to 0.78 (0.24-0.31) for the TTO, and 0.48 to 0.82 (0.24-0.34) for the SG. The mean RS, TTO, and SG scores for SSc health states were 25.3-69.7 (15.2-16.3) for the RS, 0.36-0.80 (0.25-0.31) for the TTO, and 0.50-0.81 (0.26-0.32) for the SG, depending on disease severity. CONCLUSION: Health utilities for PsA and SSc health states as assessed from the general public reflect the severity of the diseases. These descriptive findings could have implications regarding comparative effectiveness research for tests and treatments for PsA and SSc. |
format | Text |
id | pubmed-2959096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29590962010-10-22 Valuation of scleroderma and psoriatic arthritis health states by the general public Khanna, Dinesh Frech, Tracy Khanna, Puja P Kaplan, Robert M Eckman, Mark H Hays, Ron D Ginsburg, Shaari S Leonard, Anthony C Tsevat, Joel Health Qual Life Outcomes Research OBJECTIVE: Psoriatic arthritis (PsA) and scleroderma (SSc) are chronic rheumatic disorders with detrimental effects on health-related quality of life. Our objective was to assess health values (utilities) from the general public for health states common to people with PsA and SSc for economic evaluations. METHODS: Adult subjects from the general population in a Midwestern city (N = 218) completed the SF-12 Health Survey and computer-assisted 0-100 rating scale (RS), time trade-off (TTO, range: 0.0-1.0) and standard gamble (SG, range: 0.0-1.0) utility assessments for several hypothetical PsA and SSc health states. RESULTS: Subjects included 135 (62%) females, 143 (66%) Caucasians, and 62 (28%) African-Americans. The mean (SD) scores for the SF-12 Physical Component Summary scale were 52.9 (8.3) and for the SF-12 Mental Component Summary scale were 49.0 (9.1), close to population norms. The mean RS, TTO, and SG scores for PsA health states varied with severity, ranging from 20.2 to 63.7 (14.4-20.3) for the RS 0.29 to 0.78 (0.24-0.31) for the TTO, and 0.48 to 0.82 (0.24-0.34) for the SG. The mean RS, TTO, and SG scores for SSc health states were 25.3-69.7 (15.2-16.3) for the RS, 0.36-0.80 (0.25-0.31) for the TTO, and 0.50-0.81 (0.26-0.32) for the SG, depending on disease severity. CONCLUSION: Health utilities for PsA and SSc health states as assessed from the general public reflect the severity of the diseases. These descriptive findings could have implications regarding comparative effectiveness research for tests and treatments for PsA and SSc. BioMed Central 2010-10-01 /pmc/articles/PMC2959096/ /pubmed/20920309 http://dx.doi.org/10.1186/1477-7525-8-112 Text en Copyright ©2010 Khanna et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Khanna, Dinesh Frech, Tracy Khanna, Puja P Kaplan, Robert M Eckman, Mark H Hays, Ron D Ginsburg, Shaari S Leonard, Anthony C Tsevat, Joel Valuation of scleroderma and psoriatic arthritis health states by the general public |
title | Valuation of scleroderma and psoriatic arthritis health states by the general public |
title_full | Valuation of scleroderma and psoriatic arthritis health states by the general public |
title_fullStr | Valuation of scleroderma and psoriatic arthritis health states by the general public |
title_full_unstemmed | Valuation of scleroderma and psoriatic arthritis health states by the general public |
title_short | Valuation of scleroderma and psoriatic arthritis health states by the general public |
title_sort | valuation of scleroderma and psoriatic arthritis health states by the general public |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959096/ https://www.ncbi.nlm.nih.gov/pubmed/20920309 http://dx.doi.org/10.1186/1477-7525-8-112 |
work_keys_str_mv | AT khannadinesh valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic AT frechtracy valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic AT khannapujap valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic AT kaplanrobertm valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic AT eckmanmarkh valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic AT haysrond valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic AT ginsburgshaaris valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic AT leonardanthonyc valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic AT tsevatjoel valuationofsclerodermaandpsoriaticarthritishealthstatesbythegeneralpublic |